PFE - Pfizer Inc.
| Previous Close | 44.11 |
| Open | 44.33 |
| Bid | 43.38 x 1100 |
| Ask | 43.63 x 900 |
| Day's Range | 43.35 - 44.46 |
| 52 Week Range | 33.20 - 45.81 |
| Volume | 19,126,232 |
| Avg. Volume | 21,533,296 |
| Market Cap | 251.566B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | 10.99 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.07%) |
| Ex-Dividend Date | 2018-11-08 |
| 1y Target Est | N/A |
- Yahoo Finance Video•7 days ago
MARKETS: Oil heading into bear market territory
Oil moving on a government report on supply increases. Yahoo Finance's Julie Hyman and Adam Shapiro talk to Seana Smith on the floor of the NYSE.
Reuters•2 hours agoPfizer loses blockbuster drug patent fight in UK Supreme Court
Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan, and Mylan. Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.
- Reuters•3 hours ago
Pfizer loses blockbuster drug patent fight in UK Supreme Court
Pfizer (PFE.N) lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan (AGN.N), and Mylan (MYL.O). Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.
- Reuters•yesterday
Walmart, Home Depot adopt health insurer tactic in drug copay battle
Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.
- Zacks•2 days ago
Pfizer (PFE) Stock Moves -0.38%: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.
- Investor's Business Daily•2 days ago
These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
- Market Realist•2 days ago
Corbus Pharmaceuticals Holdings’ Performance in 2018
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
Market Realist•2 days agoHow Nektar Performed in the Third Quarter
Nektar Therapeutics (NKTR) released its third-quarter results on November 8. On November 6, Nektar announced a clinical oncology collaboration with Pfizer (PFE) to evaluate the combination of NKTR-214 with avelumab and talazoparib in different cancer areas. Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the comparable period of 2017.
- Insider Monkey•3 days ago
Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
- Motley Fool•3 days ago
Better Buy: Amgen Inc. vs. Pfizer Inc.
Which big drugmaker is the better pick for long-term investors?
- Zacks•5 days ago
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Motley Fool•6 days agoICU Medical Inc (ICUI) Q3 2018 Earnings Conference Call Transcript
ICUI earnings call for the period ending September 30, 2018.
- Investor's Business Daily•7 days ago
These 5 Dow Jones Stocks Just Made This Bullish Move
United Health and Microsoft led the Dow Jones stocks rally — two among five Dow stocks reclaiming the 50-day moving average.
- Zacks•6 days ago
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.
- Market Realist•6 days ago
How Analysts Rate AbbVie Stock
In November 2018, of the total 20 analysts covering AbbVie (ABBV), eight analysts have given the stock a “buy” or higher rating, nine analysts have given it a “hold” rating, and three analysts have given AbbVie a “sell” or a lower rating. The mean rating for AbbVie stock is 2.6 with a target price of $101.11, implying an upside potential of 20.9% over AbbVie’s closing price of $83.66 on November 7.
- Reuters•6 days ago
AstraZeneca sees years of growth as drug sales turn corner
Strong demand for AstraZeneca's new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement. Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018. It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which staved off a takeover bid from Pfizer four years ago, rose 2 percent by 0920 GMT on Thursday.
Market Realist•7 days agoWhat AbbVie’s Bottom Line Trend Indicates
AbbVie’s net earnings per share were $1.01 in the third quarter of 2017. AbbVie stock corrected from $123.21 on January 26, 2018, to $89.78 on April 6, 2018. Amidst the broader market turmoil in October, AbbVie stock witnessed selling pressure and fell to $77.85 on October 31.
Market Realist•7 days agoHow AbbVie Is Positioned in November
AbbVie (ABBV) operates in four therapeutic areas: immunology, oncology, virology, and neuroscience. Strong performances from AbbVie’s hematologic oncology product portfolio, solid Humira and Imbruvica sales, and stock price fluctuations have kept investors interested in the stock. In this series, we explore AbbVie’s financials, the performance of the company’s key products, analysts’ recommendations for the stock, and the company’s valuation metrics.
Market Realist•7 days agoA Look at AbbVie’s Operational Performance
AbbVie’s (ABBV) cost of products sold increased from $1.62 billion in the third quarter of 2017 to $1.83 billion in the third quarter of 2018. For fiscal 2018 and 2019, AbbVie’s gross margins are expected at 80.63% and 82.11%, respectively, as compared with gross margins of 80.47% for fiscal 2017. In comparison, fiscal 2018 gross margins of peers Johnson & Johnson (JNJ), Eli Lilly (LLY), and Pfizer (PFE) are expected at 70.43%, 75.98%, and 79.20%, respectively.
- Investing.com•7 days ago
Pfizer Rises 3%
Investing.com - Pfizer (NYSE:PFE) rose by 3.29% to trade at $44.42 by 10:41 (15:41 GMT) on Wednesday on the NYSE exchange.
- CNBC•7 days ago
'We have a lot of things in common' — Trump wants to work with Democrats on infrastructure, drugs
President Trump says at a White House press conference he hopes to work together with congressional Democrats on issues ranging from infrastructure to drug pricing. "The Democrats will come to us with a plan for infrastructure, a plan for health care, a plan for whatever they're looking at and we'll negotiate," the president says. President Donald Trump said at a White House press conference Wednesday he hopes to work with congressional Democrats on issues ranging from infrastructure to drug pricing.
- Benzinga•7 days ago
Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election
Democrats didn’t get the blue wave they hoped for Tuesday, but they picked up enough votes to take the majority in the House of Representatives, with Republicans maintaining control of the Senate. A Democratic House could provide some resistance to President Donald Trump’s trade war tariffs on China. The potential for Democrats to pressure Trump to back down on China is theoretically good news for U.S. companies that rely on Chinese supply and demand.
- Moody's•7 days ago
NMC Healthcare Sukuk Limited -- Moody's assigns Ba1 rating to NMC's trust certificates
Moody's Investors Service has today assigned a Ba1 rating to the proposed USD-denominated trust certificates (or sukuk) of NMC Healthcare Sukuk Limited. At the same time Moody's assigned a stable outlook ...
Market Realist•7 days agoWhy Pfizer’s Rare Disease Portfolio Offers a Unique Opportunity
Of this revenue, $157 million came from the US market, reflecting a YoY fall of 3%. The rare disease franchise earned revenue of $201 million from developed European markets, $90 million from other developed markets, and $83 million from emerging markets.
- Zacks•8 days ago
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $42.99, moving -1.22% from the previous trading session.
